Asmanex HFA® (mometasone furoate) – Expanded indication, new strength
August 12, 2019 - The FDA approved Merck’s Asmanex HFA (mometasone furoate) inhalation solution, for the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older.
Download PDF
